TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48 TWD | +1.05% |
|
+4.12% | -26.27% |
| 14/03 | Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 06/02 | Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer | CI |
| Sales 2022 | 22.4 729.38 1.87K | Sales 2023 | 61.41 2K 5.12K | Capitalization | 8.71B 284B 727B |
|---|---|---|---|---|---|
| Net income 2022 | -1.64B -53.42B -137B | Net income 2023 | -2.14B -69.57B -178B | EV / Sales 2022 | 59,94,27,887 x |
| Net Debt 2022 | 1.05B 34.28B 87.8B | Net Debt 2023 | 1.35B 43.98B 113B | EV / Sales 2023 | 16,39,06,538 x |
| P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-3.93
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.81% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.05% | ||
| 1 week | +4.12% | ||
| Current month | -1.44% | ||
| 1 month | -1.13% | ||
| 3 months | -26.38% | ||
| 6 months | -35.57% | ||
| Current year | -26.27% |
1 week
44.00
48.30
1 month
44.0051.20
Current year
44.0066.50
1 year
44.0089.80
3 years
44.00245.22
5 years
44.00299.78
10 years
44.001 034.21
| Managers | Title | Age | Since |
|---|---|---|---|
Kuan Hao Lin
DFI | Director of Finance/CFO | - | 18/22/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
ALLEN Chao
FOU | Founder | 78 | 08/13/08 |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 06/13/06 |
Chih Chuan Chen
BRD | Director/Board Member | - | 06/13/06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +0.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 48 | +1.05% | 392,713 |
| 25/24/25 | 47.5 | +0.64% | 176,187 |
| 24/24/24 | 47.2 | -1.56% | 339,403 |
| 23/24/23 | 47.95 | +5.73% | 880,776 |
| 22/24/22 | 45.35 | -1.63% | 888,348 |
End-of-day quote Taiwan S.E., April 26, 2024
More quotes
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.27% | 241M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6541 Stock
